The Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis) drugs in development market research report provides comprehensive information on the therapeutics under development for Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis) and features dormant and discontinued products.
GlobalData tracks 27 drugs in development for Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis) by 25 companies/universities/institutes. The top development phase for Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis) is phase ii with 13 drugs in that stage. The Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis) pipeline has 27 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis) pipeline products market are: Incyte, Chia Tai Tianqing Pharmaceutical Group and Bristol-Myers Squibb.
The key targets in the Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis) pipeline products market include Tyrosine Protein Kinase JAK2, Tyrosine Protein Kinase JAK1, and Receptor Type Tyrosine Protein Kinase FLT3.
The key mechanisms of action in the Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis) pipeline product include Tyrosine Protein Kinase JAK2 Inhibitor with ten drugs in Phase III. The Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis) pipeline products include four routes of administration with the top ROA being Oral and three key molecule types in the Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis) pipeline products market including Small Molecule, and Monoclonal Antibody.
Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis) overview
Primary myelofibrosis (PMF) is a rare bone marrow disorder marked by irregularities in blood cell production and the development of fibrous tissue within the bone marrow. Hematopoietic stem cells in the bone marrow, responsible for generating red blood cells, white blood cells, and platelets, undergo DNA changes in PMF, leading to continuous abnormal cell reproduction. Over time, these aberrant cells displace healthy cells, disrupting the production of blood cells and causing scarring in the marrow. Symptoms vary, with some individuals remaining asymptomatic initially. However, fatigue, fever, frequent infections, pale skin, night sweats, weight loss, and an enlarged spleen are eventual manifestations. Approximately 50% of patients exhibit a JAK2 gene mutation.
For a complete picture of Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
